XML 72 R55.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details) - USD ($) |  | 1 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
May 31, 2017 | Nov. 30, 2023 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Aug. 31, 2024 | Jul. 15, 2024 | Mar. 31, 2024 | Oct. 31, 2023
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Impairment loss of financial royalty assets |  |  | $ 30,572,000 | $ 924,000 | $ 0 |  |  |  |
Financial royalty assets |  |  |  |  | $ 0 |  |  |  |
Gross carrying value |  |  | 198,587,000 | 70,364,000 |  |  |  |  |
Tolerance Therapeutics (Tzield) |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Cash payments for acquisition |  | $ 20,000,000 |  |  |  |  |  |  |
Product royalty (as a percent) |  | 1.00% |  |  |  |  |  |  |
Deferred tax liability |  | $ 5,500,000 |  |  |  |  |  |  |
APEIRON |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Financial royalty assets |  |  | 106,156,000 |  |  |  | $ 106,156,000 |  |
Deferred tax liability |  |  |  |  |  |  | 18,109,000 |  |
InvIOs | APEIRON |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Financial royalty assets |  |  |  |  |  |  | 1,300,000 |  |
Qarziba | APEIRON |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Financial royalty assets |  |  |  |  |  |  | $ 104,900,000 |  |
Ovid (Soticlestat) |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Impairment loss of financial royalty assets |  |  | 30,300,000 |  |  |  |  |  |
Gross carrying value |  |  | 0 | 30,310,000 |  |  |  |  |
Ovid (Soticlestat) | Soticlestat |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Consideration paid for an interest in potential development milestone |  |  |  |  |  |  |  |  | $ 30,000,000
Interest in sales revenue (as a percent) |  |  |  |  |  |  |  |  | 13.00%
Selexis |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Impairment loss of financial royalty assets |  |  | 300,000 | 900,000 |  |  |  |  |
Gross carrying value |  |  | 205,000 | 940,000 |  |  |  |  |
Elutia (CorMatrix) |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Product royalty (as a percent) | 5.00% |  |  |  |  |  |  |  |
Gross carrying value |  |  | 9,418,000 | 13,304,000 |  |  |  |  |
Proceeds from royalties received | $ 10,000,000 |  |  |  |  |  |  |  |
(Reduction) credit loss adjustment |  |  | (5,200,000) | 3,200,000 |  |  |  |  |
Elutia (CorMatrix) | Maximum |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Additional royalties receivable under sales-based milestones | $ 10,000,000 |  |  |  |  |  |  |  |
Ensifentrine inventors |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets |  |  |  |  |  |  |  |  |
Gross carrying value |  |  | $ 15,969,000 | $ 0 |  | $ 13,600,000 |  | $ 3,800,000 |

X
- Definition Additional Royalties Receivable Under Sales-based Milestones + References No definition available. + Details
Name: | lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets + References No definition available. + Details
Name: | lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commercial License Rights, Credit Loss Adjustment + References No definition available. + Details
Name: | lgnd_CommercialLicenseRightsCreditLossAdjustment
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration Paid For An Interest In Potential Development Milestone + References No definition available. + Details
Name: | lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Financial Royalty Assets, Gross + References No definition available. + Details
Name: | lgnd_FinancialRoyaltyAssetsGross
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Impairment Loss On Financial Royalty Assets + References No definition available. + Details
Name: | lgnd_ImpairmentLossOnFinancialRoyaltyAssets
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product Royalty Percentage + References No definition available. + Details
Name: | lgnd_ProductRoyaltyPercentage
Namespace Prefix: | lgnd_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sales Contract, Interest In Sales Revenue + References No definition available. + Details
Name: | lgnd_SalesContractInterestInSalesRevenue
Namespace Prefix: | lgnd_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromRoyaltiesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_InvIOsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_QARZIBAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lgnd_SoticlestatMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_SelexisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lgnd_EnsifentrineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |